Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 9 min ago
Peer-reviewedCC BY-NC-ND 4.0Molecular Therapy Oncology

Emerging cell therapies for gastrointestinal cancers: Advances and future perspectives

  • Nobuhiko Kanaya1,2,3
  • Shinji Kuroda1
  • Kok-Siong Chen2
  • Yoshihiko Kakiuchi1
  • Toshiyoshi Fujiwara1
  1. 1Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
  2. 2Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
  3. 3Department of Medical Technology, Graduate School of Health Sciences, Okayama University, Okayama 700-8558, Japan
Read full textDOICite

Abstract

Gastrointestinal (GI) cancers, including colorectal and pancreatic cancers, remain among the most lethal cancers worldwide. These tumors often exhibit resistance to immune checkpoint inhibitors, largely due to microsatellite stability and a profoundly immunosuppressive tumor microenvironment (TME). While chimeric antigen receptor (CAR) T cell therapy has demonstrated curative potential in hematological cancers, its translation to solid tumors has been limited by challenges such as antigen heterogeneity, physical barriers to infiltration, and TME-mediated immunosuppression. Gene-editing technologies, including CRISPR-Cas9, have catalyzed the development of next-generation cellular immunotherapies. By precisely modifying T cells, natural killer (NK) cells, and mesenchymal stem/stromal cells (MSCs), it is possible to enhance their functionality, persistence, and safety. This review highlights the clinical progress of gene-edited cell therapies and specifically explores the synergistic “one-two punch” potential of engineered MSCs as TME remodeling platforms. By acting as localized delivery vehicles for cytokines or prodrug-activating enzymes, MSCs can modulate TME, thereby facilitating the infiltration and sustained cytotoxic activity of CAR T or CAR NK cells. Finally, we address critical translational challenges and propose future directions that integrate multi-omics to identify novel therapeutic agents for cellular immunotherapy in GI oncology.

Related

  1. Recent advances in loco-ablative therapies for liver cancers.
    R Orr, B Chan, E Y J Lo +1
    ESMO gastrointestinal oncologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
  2. Emerging antibody-drug conjugate (ADC) therapies: perspectives from the global patent landscape
    Tong Wu, Baijun Liu, Jiayu Jin +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefPMC
  3. Socioeconomic inequalities, phenotypic aging, and the risk of incident upper gastrointestinal cancers
    Lijuan Qiu, Yuancheng Li, Shiyin Meng +4
    BMC Public HealthPeer-reviewedCC BY-NC-ND 4.0Epidemiology & public healthCrossref
  4. Nonpharmacological interventions for frailty and sarcopenia in older adults with gastrointestinal cancers: A Bayesian network meta-analysis
    Xiaoxu Wang, Xueyuan Hui, Zhongmin Fu +6
    ISciencePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCCrossref
  5. GClnc1 as an emerging oncogenic regulator with mechanistic insights and clinical implications in human cancers
    Qing Dong, Yixin He, Rui Yu +3
    iSciencePeer-reviewedCC BY 4.0Full textCell biologyOncologyCell PressCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{kanaya2026emerging,
  title = {{Emerging cell therapies for gastrointestinal cancers: Advances and future perspectives}},
  author = {Nobuhiko Kanaya and Shinji Kuroda and Kok-Siong Chen and Yoshihiko Kakiuchi and Toshiyoshi Fujiwara},
  journal = {Molecular Therapy Oncology},
  year = {2026},
  month = oct,
  doi = {10.1016/j.omton.2026.201359},
  url = {https://doi.org/10.1016/j.omton.2026.201359},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Emerging cell therapies for gastrointestinal cancers: Advances and future perspectives
AU  - Nobuhiko Kanaya
AU  - Shinji Kuroda
AU  - Kok-Siong Chen
AU  - Yoshihiko Kakiuchi
AU  - Toshiyoshi Fujiwara
PY  - 2026
DA  - 2026/10/07
JO  - Molecular Therapy Oncology
DO  - 10.1016/j.omton.2026.201359
UR  - https://doi.org/10.1016/j.omton.2026.201359
AB  - Gastrointestinal (GI) cancers, including colorectal and pancreatic cancers, remain among the most lethal cancers worldwide. These tumors often exhibit resistance to immune checkpoint inhibitors, largely due to microsatellite stability and a profoundly immunosuppressive tumor microenvironment (TME). While chimeric antigen receptor (CAR) T cell therapy has demonstrated curative potential in hematological cancers, its translation to solid tumors has been limited by challenges such as antigen heterogeneity, physical barriers to infiltration, and TME-mediated immunosuppression. Gene-editing technologies, including CRISPR-Cas9, have catalyzed the development of next-generation cellular immunotherapies. By precisely modifying T cells, natural killer (NK) cells, and mesenchymal stem/stromal cells (MSCs), it is possible to enhance their functionality, persistence, and safety. This review highlights the clinical progress of gene-edited cell therapies and specifically explores the synergistic “one-two punch” potential of engineered MSCs as TME remodeling platforms. By acting as localized delivery vehicles for cytokines or prodrug-activating enzymes, MSCs can modulate TME, thereby facilitating the infiltration and sustained cytotoxic activity of CAR T or CAR NK cells. Finally, we address critical translational challenges and propose future directions that integrate multi-omics to identify novel therapeutic agents for cellular immunotherapy in GI oncology.
SN  - 2950-3299
ER  -